Business Context and Reporting Period
This Form 8-K Current Report was filed by Protagonist Therapeutics, Inc. on May 29, 2019, covering events occurring on May 28, 2019. The Company is a Delaware corporation listed on The Nasdaq Stock Market under the symbol PTGX and is classified as an emerging growth company.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The report focuses exclusively on executive compensation and personnel changes.
Material Changes
The primary material change reported is the appointment of Donald Kalkofen as Chief Financial Officer (CFO), effective May 28, 2019. He assumes the roles of principal financial officer and principal accounting officer. This appointment ends the interim service of Dinesh V. Patel, Ph.D., who served as interim CFO from January 11, 2019, and interim principal accounting officer from March 20, 2019.
Management Commentary and Compensation Details
The Company entered into an offer letter with Mr. Kalkofen detailing the following compensation terms:
- Base Salary: $350,000 annually.
- Discretionary Bonus: Eligible for up to 40% of the base salary.
- Equity Grant: An option to purchase 100,000 shares of Common Stock, granted as of May 31, 2019.
- Vesting Schedule: 25% vests on the one-year anniversary of the grant date, with the remaining balance vesting in equal monthly installments over the subsequent 36 months, contingent on continued service.
Mr. Kalkofen brings over 15 years of CFO experience, including prior roles at App Annie, Depomed (now Assertio Therapeutics), Align Technology, and Marketo.
Investor Verification Checklist
- Verify the full text of the Offer Letter filed as Exhibit 10.1 for complete terms and conditions.
- Confirm the vesting schedule and exercise price of the 100,000 share option grant under the 2018 Inducement Plan.
- Review subsequent filings for any updates to the Company's cash position or burn rate, as this 8-K does not provide liquidity data.
- Monitor the transition of financial reporting responsibilities from the interim officers to the newly appointed CFO.